Novo Nordisk (NOVOb.CO) on Friday raised its outlook for its full-year sales and operating profit for the third time this year, reflecting strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States.
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photoon Friday raised its outlook for its full-year sales and operating profit for the third time this year, reflecting strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States.
The Danish drugmaker said it now expects sales growth this year between 32% and 38%, from a previous forecast of 27%-33%. Novo became Europe's most valuable company this year on soaring demand for weekly injection Wegovy and its lower-dose version Ozempic.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surgeNovo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surge
Read more »
Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and WegovyEleanor Laise is a healthcare reporter for MarketWatch and is based in Washington.
Read more »
Novo Nordisk warns online offers of fake Ozempic, Wegovy are risingNovo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.
Read more »
Novo Nordisk: Online Ozempic, Wegovy Fakes RisingNovo Nordisk warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.'Novo Nordisk has seen a significant increase...
Read more »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon, Amgen and moreThese are some of the stocks posting the largest moves midday.
Read more »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and moreThese are some of the stocks posting the largest moves midday.
Read more »